Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2017)
26 slides from Cogstate's shareholder meeting presentation, Oct 25, 2017
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 25 October 2017 © 2017 Cogstate Ltd. All rights reserved.
Slide 2: Board of Directors
Board of Directors For personal use only Audit, Risk Remuneration & Compliance & Nomination Committee Committee Martyn Myer Non-Exec Chairman Yes Chair Founding Director and substantial shareholder Brad O’Connor Chief Executive Officer N/A N/A CEO since December 2005 David Dolby Non-Exec Director No
Slide 3: Non-Exec Director Appointments
Non-Exec Director Appointments For personal use only Providing Enhanced Commercial and Governance Oversight Richard Mohs Jane McAloon Independent non-executive director Independent non-executive director Appointed January 2017 (US based) Appointed January 2017 (Aust based) ▪ Retired from Eli Lilly i
Slide 4: Thank You – David Simpson
Thank You – David Simpson For personal use only Retiring from the Board of Cogstate at the conclusion of this meeting David Simpson Independent non-executive director Appointed 24 August 2004 ▪ Appointed six months after Cogstate’s IPO, David has been an independent non-executive director for most o
Slide 5: Enhanced Leadership & Expertise
For personal use only Enhanced Leadership & Expertise 5
Slide 6: Senior Executive Appointments
Senior Executive Appointments For personal use only To Further Accelerate Revenue Growth in Clinical Trials and Healthcare George Hunnewell Frank Cheng COO & President of Clinical Trials President of Healthcare Appointed November 2016 (US based) Appointed November 2016 (US based) ▪ 25 years experien
Slide 7: For personal use only
For personal use only “ We believe that brain health is profoundly important to quality of life and should be easier to measure. That’s why we so passionately apply our expertise, access to data and flexible technology to simplify the measurement of cognition.” 7
Slide 8: Leaders In Cognitive Measurement
Leaders In Cognitive Measurement For personal use only Digital brain health assessments and novel technology enhancements for traditional cognitive measures, all driven by science and operational expertise Our proven technology allow clients to We are commercialising our technology measure cognition
Slide 9: Validated Through Use in Over 1,500 Studies
Validated Through Use in Over 1,500 Studies Across Academic and Clinical Research For personal use only >50 >90 Countries Languages & Dialects >400 >70 Peer Reviewed Indications Publications 9
Slide 10: FY17 Financial Highlights
FY17 Financial Highlights For personal use only A Solid Year with Growth Across Most Core Metrics Sales contracts executed Contracted future revenues US$29.6m A$37.5m (US$28.7m) Contract delays in second half pushed Strong contracted revenue pipeline +4% awards into FY18 +10% Revenue EBITDA A$35.0m
Slide 11: Investments for Future Growth
Investments for Future Growth Investments to facilitate continued future growth within the Clinical Trials segment For personal use only as well as the launch into Clinical Practice in FY18. FY17 FY16 A$ A$ Healthcare ($1.23m) ($0.97m) - preparation for FDA submission and commercial launch of Cognig
Slide 12: Operating Results
For personal use only Operating Results Brad O’Connor - CEO 12
Slide 13: Expanded Commercial Opportunities In Clinical Trials
For personal use only Expanded Commercial Opportunities In Clinical Trials 13
Slide 14: Commercial Success Metrics
Commercial Success Metrics Clinical Trials Profit Contribution ! For personal use only 40,000,000 34,652,048 35,000,000 30,000,000 27,140,935 Building Pipeline For Future Growth 25,000,000 20,000,000 19,092,047 • Sales pipeline now exceeds US$100m AUD $ 15,702,044 15,775,169 15,000,000 • Preferred p
Slide 15: Complete Solutions for More Reliable Results
Complete Solutions for More Reliable Results For personal use only Scientific Consulting Computerised Scale Assessment Management Reliable Data For Clinical Trial Decision-making Central Monitoring Rater Training Enhanced eCOA 15
Slide 16: Enhanced Solutions Delivered in FY17
Enhanced Solutions Delivered in FY17 For personal use only Computerized Cognitive Tablet-based Rater Training Assessment eSource & Monitoring Partnered with Clinical Ink to provide Created a novel eLearning solution Adapted our technology for more that drives efficiencies in the training, flexible,
Slide 17: Global Footprint and Managed Growth
Global Footprint and Managed Growth For personal use only Global Footprint Total Headcount & Active Trials 175 London, UK Boston, MA 107 New Haven, CT Headcount 80 New York, NY 75 # of Trials 63 54 57 44 2014 2015 2016 2017 Melbourne, AU • ~275 team • Managed growth, hiring ahead of demand - 175 ful
Slide 18: FDA Clearance for U.S. Healthcare Market
For personal use only FDA Clearance for U.S. Healthcare Market 18
Slide 19: What Is Cognigram?
What Is Cognigram? For personal use only • 10-15 minute test for clinical care setting • Can be taken at home or in hospital/clinic • Assessment results instantly available to healthcare professionals • Class II medical device, reviewed and cleared by FDA • HIPAA compliant Sensitivity Ease of use Cu
Slide 20: Most Promising Clinical Applications
Most Promising Clinical Applications For personal use only Application Benefits Detect cognitive decline that • early detection for disease management could be signs of Alzheimer’s or and clinical trial referral Mild Cognitive Impairment • evaluate cognitive state Monitor Drug Side Effect during/aft
Slide 21: Cognigram Report for Healthcare Professionals
Cognigram Report for Healthcare Professionals For personal use only Patient & assessment order Information Interactive results and data visualisations Real-time baseline configuration and change score analysis Composite scores (shown) and detailed outcome measures 21
Slide 22: FY18 Goals and Objectives
FY18 Goals and Objectives For personal use only Continued Investment to Position for the Longer-term Opportunity • Increase in Clinical Trial sales, driven by more than 100% growth in sales pipeline • Increased contribution from the Clinical Trials segment • Launch and roll-out of Cognigram • Invest
Slide 23: FY18 Q1 Results
FY18 Q1 Results For personal use only Solid start to the year, providing confidence for strong H1 results • $7.5m Clinical Trial sales contracts signed (book-to-bill = 1.0) – Strongest quarter result since Q1 FY16 – Includes $0.8m “start-up agreement” that allows Cogstate to begin work, but an addit
Slide 24: For personal use only
B Cogstate Ajuo esn feuosied JOS
Slide 25: Appendix: background information
For personal use only Appendix: background information Additional investor presentations available at : cogstate.com/investors/investor-presentations/ 25
Slide 26: FY17 Summary of Financial Performance
For personal use only FY17 Summary of Financial Performance * *Other operating expenditure, includes employment expenses of A$4.9m (FY16 A$4.6m) inclusive of Board, CEO, COO, Finance team, Legal team, administrative and temporary staff. Those employment expenses are expected to remain consistent fro